FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Grants | Lung Cancer | Pharmaceuticals | Small Cell Lung Cancer